Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare rate shifts, dialysis quality scores, and clinical trial liabilities make DaVita’s SEC disclosures some of the most intricate in healthcare. Parsing a 300-page annual report or tracking last-minute 8-K updates can distract from real analysis. Stock Titan solves that problem by converting dense text into plain-English takeaways, so understanding DaVita SEC documents with AI feels effortless.
Whether you need a DaVita annual report 10-K simplified for reimbursement risk, a quick look at the latest DaVita quarterly earnings report 10-Q filing, or an alert on DaVita 8-K material events explained, every disclosure lands here seconds after EDGAR posts. Our platform instantly tags DaVita insider trading Form 4 transactions and streams DaVita Form 4 insider transactions real-time, letting you spot executive moves before the market reacts. AI-powered summaries highlight patient-mix trends, segment margins, and legal contingencies so you can move from document to decision in minutes.
Use these insights to:
- Monitor DaVita executive stock transactions Form 4 ahead of CMS rulings
- Compare dialysis economics with peer benchmarks through our DaVita earnings report filing analysis
- Review the DaVita proxy statement executive compensation to see how incentives align with patient outcomes
DaVita Inc. (DVA) director reports stock acquisition. A director of DaVita Inc. reported acquiring 411 shares of the company’s common stock on 11/15/2025 in a transaction priced at $0 per share, as disclosed on a Form 4. Following this transaction, the director beneficially owns 13,981 shares of DaVita common stock, held directly.
DaVita Inc. director reports a small stock acquisition. A DaVita Inc. (DVA) director filed a Form 4 reporting the acquisition of 411 shares of common stock on 11/15/2025 at a reported price of $0 per share. After this transaction, the director holds 411 shares as a direct owner and 2,894 shares as an indirect owner through the Wendy L. Schoppert Revocable Trust. No derivative securities were reported in this filing.
DaVita Inc. director reports a small stock acquisition. A director of DaVita Inc. (DVA) acquired 411 shares of common stock on 11/15/2025 at a reported price of $0 per share, indicating this was likely an equity grant rather than an open-market purchase. Following this transaction, the director beneficially owns 5,110 shares of DaVita common stock, held directly. No derivative securities such as options or warrants are reported as acquired or disposed of in this filing.
A DaVita Inc. (DVA) director reported acquiring 411 shares of common stock on 11/15/2025 at a stated price of $0, indicating this was likely a stock grant rather than an open-market purchase. Following this transaction, the director beneficially owns 2,089 DaVita shares, held in direct ownership. This is a routine insider ownership update showing a modest increase in the director’s equity stake.
DaVita Inc. director reports stock acquisition
A director of DaVita Inc. (DVA) reported acquiring 411 shares of DaVita common stock on 11/15/2025 in a transaction priced at $0 per share7,231 shares of DaVita common stock in direct ownership. This is a routine insider ownership update, disclosing the director’s latest equity position in the company.
DaVita Inc. director reports small stock acquisition
A director of DaVita Inc. (DVA) reported acquiring 411 shares of DaVita common stock on 11/15/2025 in a Form 4 filing. The shares were acquired at a stated price of $0, which typically indicates an equity award rather than an open-market purchase. Following this transaction, the director now beneficially owns 6,023 shares of DaVita common stock, held directly.
DaVita Inc. (DVA)11/15/2025 at a reported price of $0. Following this transaction, he is shown as holding 411 shares directly and 13,028 shares indirectly through the Marc J. Desoer and Barbara J. Desoer 1998 Trust dated September 7, 1998. The filing is reported as being made by one reporting person.
DaVita Inc. (DVA) director reports stock acquisition
A director of DaVita Inc. filed a Form 4 reporting the acquisition of 411 shares of common stock on 11/15/2025. The transaction is coded as an acquisition at a stated price of $0, which typically indicates a grant or similar award rather than an open-market purchase. Following this transaction, the reporting person beneficially owns 26,363 shares of DaVita common stock, held in direct ownership. The filing is made by a single reporting person and notes the individual’s role as a Director of the company.
DaVita Inc. (DVA) disclosed a Form 4 showing its Chief Executive Officer, who is also a director, had 5,165 shares of common stock withheld on 11/15/2025. These shares were withheld to cover tax obligations arising from the vesting of 12,474 restricted stock units, representing 33.333% of the original grant made on November 15, 2024. After this tax-withholding transaction, the reporting person directly beneficially owns 888,915 shares of DaVita common stock.
The Vanguard Group filed Amendment No. 14 to Schedule 13G reporting a passive stake in DaVita Inc. (DVA) as of 09/30/2025. Vanguard reported 4,227,904 shares beneficially owned, representing 5.91% of DaVita’s common stock.
Vanguard reported 0 shares with sole voting power and 214,553 with shared voting power. It reported 3,919,715 shares with sole dispositive power and 308,189 with shared dispositive power. The filing was made as an investment adviser (IA) and includes a certification that the securities are held in the ordinary course of business and not to change or influence control.
FAQ
What is the current stock price of Davita (DVA)?
What is the market cap of Davita (DVA)?
